Shaker A Mousa Selected Research

Oral Administration

1/2020	β-glucan administration improves growth performance and gut health in New Zealand White and APRI rabbits with different breed responses.
2/2014	Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.
3/2008	Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
1/2002	Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shaker A Mousa Research Topics

Disease

170	Neoplasms (Cancer) 05/2023 - 01/2002
31	Thrombosis (Thrombus) 01/2023 - 01/2002
28	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2002
25	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2008
15	Pancreatic Neoplasms (Pancreatic Cancer) 05/2023 - 06/2012
15	Inflammation (Inflammations) 01/2022 - 05/2005
15	Hemorrhage 01/2022 - 08/2002
13	Glioblastoma (Glioblastoma Multiforme) 02/2023 - 07/2006
12	Cardiovascular Diseases (Cardiovascular Disease) 12/2022 - 05/2007
10	Carcinoma (Carcinomatosis) 08/2022 - 10/2004
8	Neuroblastoma 08/2022 - 01/2008
8	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 05/2010
7	Venous Thrombosis (Deep-Vein Thrombosis) 08/2009 - 01/2002
6	Pain (Aches) 08/2022 - 08/2007
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2021 - 09/2016
6	Body Weight (Weight, Body) 12/2020 - 01/2002
6	Diabetes Mellitus 05/2020 - 01/2009
6	Necrosis 01/2020 - 08/2014
6	Obesity 01/2020 - 10/2010
6	Venous Thromboembolism 01/2020 - 04/2002
6	Hypothyroidism 01/2018 - 07/2006
6	Macular Degeneration (Age-Related Maculopathy) 01/2013 - 01/2008
6	Thrombocytopenia (Thrombopenia) 04/2007 - 08/2002
5	Infections 08/2022 - 01/2009
5	COVID-19 02/2022 - 01/2020
5	Sickle Cell Anemia (Hemoglobin S Disease) 01/2022 - 08/2007
5	Hypoxia (Hypoxemia) 01/2022 - 05/2009
5	Hypercholesterolemia 01/2022 - 04/2005
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 05/2010
5	Type 2 Diabetes Mellitus (MODY) 12/2020 - 10/2010
5	Colorectal Neoplasms (Colorectal Cancer) 03/2020 - 01/2018
5	Colonic Neoplasms (Colon Cancer) 03/2020 - 07/2015
5	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 01/2012
5	Acute Coronary Syndrome 01/2015 - 01/2010
4	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2006
4	Liver Neoplasms (Liver Cancer) 01/2022 - 01/2019
4	Melanoma (Melanoma, Malignant) 01/2022 - 12/2006
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 01/2011
4	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 05/2016
4	Carcinogenesis 05/2020 - 03/2009
4	Anemia 01/2020 - 01/2010
4	Pathologic Neovascularization 12/2019 - 10/2004
4	Diabetic Retinopathy (Retinopathy, Diabetic) 05/2019 - 01/2008

Drug/Important Bio-Agent (IBA)

54	IntegrinsIBA 01/2023 - 08/2002
48	Thyroid HormonesIBA 01/2023 - 07/2006
47	tetraiodothyroacetic acid (TA(4))IBA 05/2023 - 01/2008
28	Thyroxine (Levothyroxine)FDA LinkGeneric 04/2022 - 07/2006
24	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2021 - 01/2002
23	AnticoagulantsIBA 01/2022 - 02/2002
21	Hormones (Hormone)IBA 01/2023 - 01/2008
20	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 02/2002
15	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 01/2008
15	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2010
12	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2023 - 02/2002
12	Cell Surface ReceptorsIBA 01/2022 - 07/2006
12	CytokinesIBA 01/2022 - 05/2007
12	AntioxidantsIBA 01/2022 - 11/2011
11	Tinzaparin (Innohep)FDA Link 03/2018 - 01/2002
10	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 02/2023 - 12/2019
10	TriazolesIBA 02/2023 - 12/2019
10	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 04/2022 - 05/2009
10	Thromboplastin (Tissue Factor)IBA 01/2021 - 07/2003
9	thymoquinoneIBA 01/2022 - 01/2018
9	Warfarin (Coumadin)FDA LinkGeneric 03/2015 - 02/2002
8	LipidsIBA 05/2023 - 01/2009
8	LigandsIBA 01/2023 - 01/2008
8	ChitosanIBA 08/2022 - 01/2012
8	TeaIBA 01/2022 - 03/2009
8	ResveratrolIBA 03/2020 - 01/2005
7	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2022 - 02/2008
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 09/2003
6	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2015
6	Estrogen ReceptorsIBA 01/2022 - 11/2009
6	Hemoglobins (Hemoglobin)IBA 01/2022 - 01/2010
6	PolyphenolsIBA 01/2018 - 03/2009
5	Peptides (Polypeptides)IBA 01/2023 - 09/2003
5	Antineoplastic Agents (Antineoplastics)IBA 04/2022 - 01/2009
5	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 01/2022 - 03/2009
5	nano-diamino-tetracIBA 10/2021 - 10/2016
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2005
5	Angiogenesis InhibitorsIBA 01/2018 - 01/2002
5	Integrin alphaVbeta3IBA 01/2013 - 07/2006
5	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2010 - 01/2004
5	Hemostatics (Antihemorrhagics)IBA 01/2010 - 11/2005
4	P-SelectinIBA 01/2023 - 06/2012
4	EnzymesIBA 01/2022 - 01/2004
4	CurcuminIBA 01/2022 - 01/2020
4	benzylguanidineIBA 01/2022 - 01/2020
4	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2022 - 01/2020
4	Interleukin-6 (Interleukin 6)IBA 11/2021 - 01/2018
4	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 02/2011
4	Polylactic Acid-Polyglycolic Acid CopolymerIBA 01/2021 - 12/2013
4	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2021 - 05/2016
4	Glycoproteins (Glycoprotein)IBA 01/2021 - 04/2002
4	Enoxaparin (Lovenox)FDA LinkGeneric 08/2019 - 12/2006
4	Retinaldehyde (Retinal)IBA 05/2019 - 03/2008

Therapy/Procedure

62	Therapeutics 01/2023 - 04/2002
41	Drug Therapy (Chemotherapy) 05/2023 - 02/2002
8	Radiotherapy 01/2022 - 07/2003
4	Oral Administration 01/2020 - 01/2002